Pharma Equity Group
Research Pharma Equity Group (PEG.CO) on Bullrun: market cap DKK 100.17M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPEG.CO
- ExchangeXCSE
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencyDKK
- Market capDKK 100.17M
- Financial periodFY2025
- RevenueDKK 0
- Net income-DKK 25.38M
- Free cash flow-DKK 17.66M
Valuation Snapshot
latest market cap is DKK 100.17M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | DKK 0 | -DKK 25.38M | -DKK 17.66M | n/a | -0.02 | DKK 498.00K | DKK 8.06M | DKK 25.47M |
| FY2024 | DKK 0 | -DKK 40.61M | -DKK 22.86M | n/a | -0.02 | DKK 4.23M | DKK 11.05M | DKK 32.69M |
| FY2023 | DKK 0 | -DKK 24.35M | -DKK 16.70M | n/a | -0.02 | DKK 4.23M | DKK 30.22M | DKK 25.33M |
| FY2022 | DKK 0 | -DKK 9.44M | -DKK 2.87M | n/a | -0.01 | DKK 182.00K | DKK 22.84M | DKK 46.05M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-16 | DKK 100.17M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 DKK.
About Pharma Equity Group
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Pharma Equity Group's market cap?
Pharma Equity Group's market capitalization is DKK 100.17M.
What does Pharma Equity Group do?
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement.